Table 1.
In vitro activity of dalbavancin against Gram-positive and anaerobic organisms
| Organism | Isolates (n) | MIC90 (μg/ml) | MIC range (μg/ml) |
|---|---|---|---|
| Staphylococci | |||
| Quin/dalfo resistant (38) | 8 | NA | 0.03–0.06 |
| Vancomycin intermediate (38) | 10 | 0.06 | 0.06–2 |
| Staphylococcus aureus (25, 39, 40, 42) | 4243 | 0.06 | ≤ 0.008–0.5 |
| Methicillin susceptible (25, 27, 40–44, 47, 48) | 4838 | 0.06–0.5 | ≤ 0.008–0.5 |
| Methicillin resistant (25, 27, 40–44, 47, 48) | 2726 | 0.06–1 | ≤ 0.015–1 |
| Glycopeptide intermediate (25, 41) | 29 | 1–2 | 0.06–16 |
| Linezolid non-susceptible (25) | 5 | NA | 0.03–0.06 |
| Staphylococcus coagulase negative (25, 38, 40, 42) | 1775 | 0.06–0.12 | ≤ 0.008–1 |
| Methicillin susceptible (25, 27, 40–44, 47, 48) | 682 | 0.06–0.5 | ≤ 0.008–0.6 |
| Methicillin resistant (25, 27, 40–44, 47, 48) | 2100 | 0.06–0.5 | ≤ 0.008–1 |
| Vancomycin non-susceptible (25) | 11 | 1 | 0.25–2 |
| Teicoplanin resistant (38) | 15 | 0.25 | 0.03–0.25 |
| Staphylococcus epidermidis | |||
| Methicillin susceptible (27, 41) | 13 | 0.25–0.5 | ≤ 0.03–0.25 |
| Methicillin resistant (27, 41) | 12 | 0.25 | ≤ 0.03–1 |
| Staphylococcus haemolyticus | |||
| Methicillin susceptible (27) | 10 | 0.13 | ≤ 0.03–0.25 |
| Methicillin resistant (27) | 12 | 0.5 | ≤ 0.03–4 |
| Streptococcus pneumoniae (25, 40, 42, 44, 46) | 1422 | ≤ 0.03–0.06 | 0.004–0.125 |
| Penicillin susceptible (25, 27, 40, 42, 48) | 1647 | 0.016–0.06 | 0.004–0.06 |
| Penicillin non-susceptible (25, 27, 38, 40, 42, 48) | 969* | ≤ 0.016–0.03 | ≤ 0.008–0.25 |
| Ceftriaxone resistant (38) | 16 | ≤ 0.016 | ≤ 0.016–0.03 |
| Streptococcus pyogenes (25, 27) | 211 | 0.015 | ≤ 0.002–0.06 |
| Erythromycin susceptible (25) | 161 | 0.015 | ≤ 0.002–0.06 |
| Erythromycin resistant (25) | 45 | 0.015 | ≤ 0.002–0.06 |
| Viridans group streptococci (25, 40, 42, 44) | 313 | 0.016–0.03 | ≤ 0.002–0.06 |
| Penicillin susceptible (25, 48) | 130 | 0.03 | ≤ 0.002–0.06 |
| Penicillin non-susceptible (25, 27, 48) | 6† | 0.03 | ≤ 0.008–0.06 |
| Erythromycin susceptible (24) | 21 | 0.03 | ≤ 0.002–0.03 |
| Erythromycin resistant (25) | 31 | 0.03 | ≤ 0.002–0.06 |
| β-Haemolytic streptococci (25, 40, 42, 44, 48) | 757 | 0.015–0.06 | ≤ 0.002–0.25 |
| Streptococcus agalactiae (25) | 52 | 0.015 | 0.008–0.06 |
| Enterococcus spp. (40, 42) | 2062 | 0.12–16 | ≤ 0.008 to > 16 |
| Vancomycin susceptible (27, 40, 42, 44) | 1606 | 0.06–0.5 | ≤ 0.008–1 |
| Vancomycin resistant (39, 40, 42, 44) | 592 | > 16–32 | ≤ 0.015 to > 32 |
| vanA resistant (27, 38) | 79 | 32 to > 128 | 0.03 to > 128 |
| vanB resistant (27, 38) | 21 | 0.12–1 | 0.02–2 |
| Linezolid resistant (39) | 9 | NA | ≤ 0.015 to > 32 |
| Enterococcus faecalis (48) | |||
| Vancomycin susceptible (48) | 586 | 0.06 | ≤ 0.015–4 |
| Vancomycin resistant (38, 48) | 34 | 32 | ≤ 0.015 to > 32 |
| Enterococcus faecium | |||
| Vancomycin susceptible (48) | 77 | 0.12 | ≤ 0.015–4 |
| Vancomycin resistant (38, 48) | 92 | 32 | 0.03 to > 32 |
| Quin/dalfo resistant (38) | 29 | 0.12‡–8§ | ≤ 0.016 to > 32 |
| Actinomyces spp. (28) | 38 | 0.5 | 0.03–0.5 |
| Bacillus spp. (40, 44) | 25 | 0.12–0.25 | 0.016–2 |
| Clostridium spp. (28) | 16 | 0.5 | ≤ 0.015–1 |
| Clostridium difficile (28) | 26 | 0.25 | 0.125–0.5 |
| Clostridium perfringens (28) | 10 | 0.125 | 0.03–0.125 |
| Corynebacterium spp. (28, 40, 44) | 51 | ≤ 0.03–0.5 | ≤ 0.015–1 |
| Corynebacterium jeikeium (28, 44) | 20 | 0.5 | ≤ 0.03–0.5 |
| Lactobacillus spp. (28) | 23 | > 32 | 0.06 to > 32 |
| Listeria spp. (48) | NA | 0.06 | NA |
| Micrococcus spp. (40) | 13 | 0.03 | ≤ 0.008–0.03 |
| Peptostreptococcus spp. (28) | 30 | 0.25 | ≤ 0.015–0.5 |
| Propionibacterium spp. (28) | 15 | 0.5 | 0.03–0.5 |
Permission for reprint granted by Ann Pharmocother; 2006; 40: 449–60.
*
Includes penicillin-non-susceptible, penicillin-intermediate and penicillin-resistant isolates.
†
Includes penicillin-non-susceptible and penicillin-resistant isolates.
‡
vanA negative isolates.
§
vanA positive isolates. MIC, minimum inhibitory concentration; NA, not available; quin/dalfo, quinupristin/dalfopristin; vanA, vancomycin-resistant enterococci possessing the vanA gene.